Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Ciforadenant |
| Trade Name | |
| Synonyms | CPI-444|CPI 444|CPI444|V81444||V-81444 |
| Drug Descriptions |
Ciforadenant (CPI-444) is an antagonist of the adenosine receptor A2aR, which may relieve adenosine-mediated immune suppression and enhance antitumor activity (PMID: 29923026, PMID: 30131376). |
| DrugClasses | Adenosine Targeting 24 |
| CAS Registry Number | 1202402-40-1 |
| NCIT ID | C125659 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Ciforadenant | Atezolizumab Ciforadenant | 0 | 2 |
| Ciforadenant | Ciforadenant | 0 | 2 |
| Ciforadenant + CPI-006 | CPI-006 Ciforadenant | 0 | 1 |
| Ciforadenant + Daratumumab | Ciforadenant Daratumumab | 0 | 1 |
| Ciforadenant + Ipilimumab + Nivolumab | Ciforadenant Ipilimumab Nivolumab | 0 | 1 |